Image source: Photo.com
The HPV vaccine is a vaccine to prevent human papillomavirus infection and is effective in preventing cervical cancer and other HPV-related diseases. The World Health Organization recommends that women receive the HPV vaccine during puberty, and men can also benefit from it. Recently, some self-media posted a video on social platforms saying that vaccination with the nine-valent HPV vaccine will lead to a 40% drop in fertility. In response to the above remarks, many doctors from various disciplines in China responded and refuted the rumors.
Wang Yanxia, deputy chief physician of the Department of Gynecology at Dongzhimen Hospital of Beijing University of Chinese Medicine, said, "Under normal circumstances, HPV vaccination does not affect fertility. She said that no matter what type of HPV vaccine is vaccinated, it can effectively prevent and reduce the incidence of cervical cancer, "so female friends should still get vaccinated when they should be vaccinated." However, in order to better protect the fetus and ensure the effectiveness of vaccination, HPV vaccination is not recommended for women who are trying to conceive, pregnant women and breastfeeding women.
Chen Bo, deputy chief physician of the Department of Urology of Shandong Provincial Hospital, also posted a video response, "Why don't you say that (the fertility rate) has dropped by 400%? Chen Bo explained, "HPV itself is skin-loving, it is on the skin and mucous membranes, it does not go elsewhere, it does not go into the blood, you don't care what you fight, it is aimed at such a place, and it does not cause immune response in other places." ”
Liu Yangsheng, deputy chief physician of the Department of Dermatology of Lu'an People's Hospital, said: "This statement is simply nonsense, whether it is a drug or something, if its side effect is infertility, the state cannot allow it to be used again, this is the biggest side effect." She stressed that it is nonsense to say that this vaccine, which is widely used globally, affects fertility.
Lei Ling, deputy chief physician of the Department of Obstetrics and Gynecology of Chongqing Maternal and Child Health Hospital, said that in response to the impact of HPV vaccine and infertility, the WHO organization has done a study and concluded that HPV vaccine is safe and has no causal relationship with ovarian insufficiency or infertility. "In addition, our HPV vaccine has been tested in hundreds of thousands of clinical trials before it is marketed, so there is no such thing as 'vaccination is acting as a guinea pig'. ”
- HPV vaccine is an effective means to prevent cervical cancer
Cervical cancer is the most common gynecological malignant tumor, with a high mortality rate, and even ranks first in some developing countries, seriously endangering women's health. Since 2009, the state has included cervical cancer screening in a major public health service project to deepen the reform of the medical and health system, and provided free cervical cancer screening for women in rural areas. So far, the national cervical cancer screening program has covered nearly 2,600 counties and cities across the country, and nearly 120 million people have been screened free of charge. In terms of disease prevention, the human papillomavirus (HPV) vaccine is a powerful means of preventing cervical cancer.
-- The number of HPV vaccine batches issued has increased significantly
From 2017 to 2020, the batch release of HPV vaccines in mainland China showed an increasing trend year by year. In 2020, the number of HPV batches issued was 15,431,700 units/bottles/bags. According to the breakdown of products, the batch release of HPV quadrivalent and 9-valent vaccines has increased year by year, and the batch release volume of HPV bivalent vaccine has changed relatively steadily. In 2020, the dual-valent batch issuance volume was 3,145,800 pieces/bottle/bag, the four-valent batch issuance volume was 7,219,500 pieces/bottle/bag, and the batch issuance volume of the nine-valent HPV pair was 5,066,400 pieces/bottle/bag. In the first four months of 2021, 5,428,900 HPV vaccines were released in batches; Among them, 2.097 million bivalent vaccines, 2.1262 million quadrivalent vaccines, and 1.2057 million nine-valent vaccines were issued. In 2021, the batch release of HPV vaccines in mainland China is expected to exceed 20 million, and due to the launch of domestic bivalent HPV vaccines, the batch release of bivalent vaccines is expected to exceed 4.5 million.
Note: CCIC will no longer disclose the number of batches issued after April 2021, and the above data for the whole year of 2021 is an estimate and is for reference only.
-- A number of HPV vaccines are expected to be marketed in a centralized manner
According to the information of the CDE, many companies in China are conducting clinical trials of HPV vaccines. Among them, the nine-valent HPV vaccine has the most companies under development, Merck, Recbio, Wantai Biotech, Kangle Guard, Bowei Biotech, and Chengdu Institute have all applied for phase III clinical trials, while companies such as Runze Biotech and Yum Biotech are applying for phase I clinical trials. At present, a large number of HPV vaccines in mainland China are in the phase III clinical trial and waiting for approval, and a number of vaccines are expected to be marketed in a centralized manner.
According to the report of the Prospective Industry Research Institute, the sales of HPV vaccine products on the market in 2021 will be about 6 billion US dollars, and with the growth of emerging markets such as China, the global cervical cancer vaccine market is expected to grow at a growth rate of about 8% in the future, and is expected to be close to 10 billion US dollars in 2027.
Wu Yinglan, director of the women's health department of Hunan Provincial Maternal and Child Health Hospital, said that from the perspective of public health, cervical cancer has a high incidence and great harm in women, so when the number of vaccines cannot meet the needs of men and women, women are still guaranteed to be vaccinated first. However, in the future, when the number of vaccines is sufficient, it will definitely become a general trend for men and women to be vaccinated together.
According to the latest research report of Founder Securities, it is expected that the size of China's HPV vaccine market is expected to reach 73 billion yuan in 2031, with a compound annual growth rate of 8.6% from 2022 to 2031, thanks to the successful completion of phase III clinical trials and the release of production capacity of China's HPV vaccine under development, the increasing awareness of target population vaccination and the potential development and release of the male market.
Prospective Economist APP Information Group
For more research and analysis of this industry, please refer to the "Analysis Report on Market Prospect and Investment Strategic Planning of China's Cervical Cancer (HPV) Vaccine Industry" by Qianzhan Industry Research Institute.
At the same time, the Prospective Industry Research Institute also provides solutions such as industrial big data, industrial research reports, industrial planning, park planning, industrial investment, industrial mapping, smart investment promotion system, industry status certificate, IPO consulting/fundraising and investment feasibility study, and specialized and special new small giant declaration. To quote the content of this article in any public information disclosure such as prospectus and annual report, formal authorization from Qianzhan Industry Research Institute is required.
More in-depth industry analysis is available in the [Prospective Economist APP], and you can also communicate and interact with 500+ economists/senior industry researchers. More enterprise data, enterprise information, and enterprise development are all in the [Qichamao APP], the most cost-effective and most comprehensive enterprise query platform.